MedTrace Logo

Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）

NCT05087706 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 182

Last updated 2021-10-21

No results posted yet for this study

Summary

To explore the feasibility, efficacy and safety of determining the treatment regimen based on genomic profiling in patients with locally advanced and advanced salivary gland cancer.

Conditions

  • Salivary Gland Neoplasms

Interventions

DRUG

Pyrotinib

Pyrotinib 400mg qd po

DRUG

Bicalutamide

Bicalutamide was administered orally at a daily dose of 50 mg

DRUG

Leuprorelin

Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks

Sponsors & Collaborators

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-30
Primary Completion
2023-03-19
Completion
2023-09-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05087706 on ClinicalTrials.gov